Medibio partners with US company for new clinical trial

Latest News

Medibio (ASX:MEB), a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of certain mental health conditions, has announced a new Clinical Trial Agreement (CTA) with MedBridge Healthcare.

The agreement will support the development of Medibio’s Sleep Analysis of Depressive Burden (SADB) trial.

The company said the SADB trial aims to identify clinical depressive burden in patients with sleep disturbance who undergo a sleep study in a clinical environment.

MedBridge is a leading provider of sleep laboratory management services in the US. It is operating over 130 sleep disorder diagnostic centres and performs over 70,000 sleep disorder diagnostic procedures annually.

MedBridge partners with hospitals and physician practices to offer comprehensive, fully-integrated services for the identification, testing, diagnosis, therapeutic coordination, and long-term care management of patients with sleep disorders.

Under the CTA, MedBridge, in collaboration with Ohio Sleep Solutions, will coordinate research guidelines and services for the purposes of the SADB trial to help fast-track patient recruitment.

John Mathias, chief development officer of MedBridge, said, “As the leading sleep management service provider in the US, we are excited about the potential of Medibio’s technology and its clinical applications. The objective identification of depression in patients that suffer certain sleep disorders is an unmet need and we are pleased to be working with Medibio to fast-track patient recruitment for the SADB trial.”

According to Claude Solitario, managing director of Medibio, “We are delighted to have MedBridge as a partner for our Sleep Analysis of Depressive Burden trial. Their expertise and reputation in sleep medicine in the United States is exemplary, and the size of MedBridge’s operations will help ensure that our SADB trial will be undertaken quickly and efficiently. MedBridge’s participation in this collaboration underscores the importance of our endeavour and attests to the quality of our research team.”